Key Insights

Highlights

Success Rate

91% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.1%

2 terminated out of 49 trials

Success Rate

90.9%

+4.4% vs benchmark

Late-Stage Pipeline

22%

11 trials in Phase 3/4

Results Transparency

30%

6 of 20 completed with results

Key Signals

6 with results91% success

Data Visualizations

Phase Distribution

39Total
Not Applicable (23)
P 2 (5)
P 3 (1)
P 4 (10)

Trial Status

Completed20
Recruiting15
Not Yet Recruiting10
Terminated2
Withdrawn1
Enrolling By Invitation1

Trial Success Rate

90.9%

Benchmark: 86.5%

Based on 20 completed trials

Clinical Trials (49)

Showing 20 of 20 trials
NCT07193407Not ApplicableRecruitingPrimary

INOPASE - Performance and Safety Study of a Personalised SNM System

NCT07545148Not Yet RecruitingPrimary

Real-world Experiences and Voices Exploring the Actual Lived Burden of OAB: A Mixed-methods Multi-country PROMs Study on OAB Patients' Quality of Life

NCT07300904Not ApplicableNot Yet RecruitingPrimary

Tensi+ for Treating Overactive Bladder

NCT07553065Phase 2Not Yet RecruitingPrimary

RELIEVE Study: NT 201 Intravesical Administration Using Vibe System (ViXe Combination Product) for the Treatment of Idiopathic Overactive Bladder

NCT06944392Not ApplicableRecruitingPrimary

Evaluating Pumpkin Seed Oil Extract Supplementation on Bladder Function

NCT07540273Not ApplicableNot Yet RecruitingPrimary

Effectiveness of Ambulatory Transcutaneous Tibial Nerve Stimulation for Overactive Bladder

NCT07335484Not ApplicableNot Yet Recruiting

Aquarius Pilot Study to Evaluate the New Axonics Trial System

NCT06789406Not ApplicableRecruiting

PMCF Study of the Axonics SNM System Model 5101 (R20) for the Indication of OAB

NCT07473310Phase 4RecruitingPrimary

Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women

NCT07405554Phase 2RecruitingPrimary

Zinc Supplementation With Botulinum Toxin for Overactive Bladder

NCT05702294Not ApplicableCompleted

Electronic Urinary Flowmeter to Improve Accuracy of Bladder Diaries .

NCT07416968Phase 4RecruitingPrimary

Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study

NCT06780163Phase 4CompletedPrimary

Effect of Vaginal Estrogen on Alterations in the Urine Microbiome of Menopausal Women With Overactive Bladder

NCT07195656Not ApplicableRecruitingPrimary

Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)

NCT07391878Phase 2Not Yet RecruitingPrimary

Evaluate the Safety and Efficacy of TRG-200 KIT in Patients With Refractory Overactive Bladder.

NCT06885099Not ApplicableCompletedPrimary

Ease of Use Study of the FemPulse System

NCT07209397Not ApplicableRecruiting

Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women

NCT07371000Not ApplicableRecruitingPrimary

Early Detection of OAB and Elimination of Negative Impact on Quality of Life

NCT07279142Not ApplicableNot Yet RecruitingPrimary

Efficacy and Safety of 7 Millimeters Vaginal Radiofrequency in Overactive Bladder

NCT07030803Not ApplicableRecruitingPrimary

Comparative Study of the Efficacy of Treatment of Idiopathic Overactive Bladder (OAB) in Children: Oxybutynine vs. Transcutaneous Neurostimulation

Scroll to load more

Research Network

Activity Timeline